• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Brexit means little for biotech stocks, analyst says

    Brexit means little for biotech stocks, analyst says

  2. Health-care stocks rally as Medicare cost-cutting not triggered

    Health-care stocks rally as Medicare cost-cutting not triggered

  3. Global Spinal Cord Injury Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: Athersys, Lpath, Tumorend - Research and Markets

    Global Spinal Cord Injury Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: Athersys, Lpath, Tumorend - Research and Markets

  4. CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

    CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

  5. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  6. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  7. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  8. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

  9. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  10. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.